Purdue researchers create biocompatible nanoparticles to enhance systemic delivery of cancer immunotherapy

Purdue University researchers have reported on their efforts to develop and validate poly (lactic-co-glycolic acid), or PLGA, nanoparticles modified with adenosine triphosphate, or ATP, to enhance immunotherapy effects against malignant tumors. They found that tumors grew slower in mice treated with paclitaxel ((a chemotherapy drug used to treat several types of cancers) ) enclosed within ATP-modified nanoparticles than in mice treated with paclitaxel in non-modified nanoparticles.